Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.

摘要: Neoadjuvant platin-based therapy is accepted as a standard for advanced esophageal adenocarcinoma (EAC). Patients who respond have better survival prognosis, but still significant number of responder patients die from tumor recurrence. Molecular markers prognosis in neoadjuvantly treated EAC not been identified yet. We investigated the epidermal growth factor receptor (EGFR) and chemotherapy resistance these patients. Two patient cohorts, either by neoadjuvant cisplatin-based followed surgery (n=86) or surgical resection (n=46) were analyzed EGFR protein expression gene copy number. Data correlated with clinical histopathological response, disease-free overall survival. In case overexpression, responders was poor non-responders. Responders had significantly than non-responders only if level (p=0.0152) (p=0.0050) low. Comparing primary patients, tumors non-responder more frequently exhibited providing evidence that indicating resistance. overexpression are independent adverse prognostic factors chemotherapy-treated particularly responders. Furthermore, involved to chemotherapy.